The Quantellect read.As of Nov 19, 2026, 7 active firms cover CAMP4 THERAPEUTICS CORPORATION: 7 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets range widely, $6.00 to $15.00 (about 2.5x), a sign of real disagreement on valuation. The average target of $9.86 sits 140% above the current $4.10. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 6 to 7 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.14 next quarter toward $-0.84 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS7 active firms
Buy
Strong Buy00%
Buy7100%
Neutral00%
Sell00%
Strong Sell00%
Based on 7 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.86
+140.4% upside
Average target across 7 active firms as of Nov 19, 2026 vs $4.10 current
Highest Target$15.00
Average Target$9.86
Lowest Target$6.00
Detailed analyst forecasts for CAMP
Showing 1–7 of 7 named analysts shown · 7 active firms in the rating projection
As of Nov 19, 2026, 7 of 7 active firms rate CAMP a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
CAMP EPS & revenue forecast
EPS · NEXT QUARTER
$-0.14
Range $-0.16 – $-0.12 · 4 analysts · -55% YoY
Next period, 4 analysts expect CAMP4 THERAPEUTICS CORPORATION to earn $-0.14 a share (range $-0.16 – $-0.12), versus $-0.32 a year earlier. Full-year consensus is $-1.21, growing to $-0.84 the year after.
REVENUE · NEXT QUARTER
$2.1M
Range $0 – $3.3M · 4 analysts · +65% YoY
Revenue is expected to reach $2.1M (range $0 – $3.3M), +65.4% year-over-year. Full-year consensus is $6.7M, rising to $6.3M next year.
Top analysts covering CAMP4 THERAPEUTICS CORPORATION
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CAMP.
#1
Keay Nakae
Chardan Capital · Rank #130
Buy
$6.00+46.3% to target
Overall win rate
41%
+ Follow
#2
Anupam Rama
JP Morgan · Rank #171
Buy
$9.00+119.5% to target
Overall win rate
48%
+ Follow
#3
Joseph Stringer
Needham · Rank #256
Buy
$8.00+95.1% to target
Overall win rate
36%
+ Follow
#4
Edward Tenthoff
Piper Sandler · Rank #460
Buy
$15.00+265.9% to target
Overall win rate
29%
+ Follow
#5
YZ
Yun Zhong
Wedbush
Buy
$8.00+95.1% to target
Coverage
—
+ Follow
CAMP stock forecast FAQ
What is CAMP's average 12-month price target?+
The 7 active firms with a live target average $9.86 for CAMP4 THERAPEUTICS CORPORATION over the next 12 months, ranging from a $15.00 high to a $6.00 low, as of Nov 19, 2026.
Is CAMP stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 7 active firms as of Nov 19, 2026, 7 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for CAMP?+
The Street-high target is $15.00 (Oppenheimer), and the Street-low is $6.00 (Chardan Capital). The average of all 7 active-firm targets is $9.86.
How many active Wall Street firms cover CAMP?+
7 active firms have a recognized rating on CAMP4 THERAPEUTICS CORPORATION as of Nov 19, 2026, and 7 active firms carry a live 12-month price target.
Who is the most accurate analyst covering CAMP?+
Among analysts who currently cover CAMP, Keay Nakae of Chardan Capital has the strongest overall Quantellect track record (Rank #130). Their current call is Buy with a $6.00 target.
What is CAMP4 THERAPEUTICS CORPORATION's projected EPS for next quarter?+
The consensus estimate is $-0.14 per share (range $-0.16 – $-0.12) across 4 analysts. Full-year EPS is projected at $-1.21, rising to $-0.84 the following year.
How much revenue is CAMP4 THERAPEUTICS CORPORATION expected to report next quarter?+
Consensus revenue is $2.1M (range $0 – $3.3M). Full-year revenue is projected at $6.7M, growing to $6.3M next year.
Have analysts been upgrading or downgrading CAMP lately?+
As of Nov 19, 2026, 7 of 7 active firms rate CAMP a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CAMP calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.